Last reviewed · How we verify
NCT06162962
Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient
trial testing Retrospective analysis in Osteosarcoma in 345 participants. Completed in 23 November 2023.
23 November 2023
Quick facts
| Lead sponsor | Changye Zou |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 345 |
| Start date | 1 January 2000 |
| Primary completion | 23 November 2023 |
| Estimated completion | 23 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Retrospective analysis
Conditions studied
- Osteosarcoma — all drugs for Osteosarcoma →
- Pediatric — all drugs for Pediatric →
- Lower Limb Injury — all drugs for Lower Limb Injury →
- Outcome — all drugs for Outcome →
Sponsor
Changye Zou
Who can join
Adults 4 to 14, any sex, with Osteosarcoma or Pediatric. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective analysis of specific characteristics of complications and long-term oncological and function outcomes in lower-limb osteosarcoma pediatric patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of oncological and functional outcomes in Lower-limb osteosarcoma pediatric patients: a large single-center retrospective cohort study.
Xu M, Tu J, Huang Y, Wang B, et al · · 2024 · cited 8× · PMID 38471042 · DOI 10.1097/js9.0000000000001340
Verify or expand the search:
- PubMed search for NCT06162962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Retrospective analysis
Trials testing the same drug.
- NCT04266938 — Impact of Rapid ART Initiation on Retention in Care in the Southern US · NA · completed
- NCT04461002 — Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Inciden · completed
Other recruiting trials for Osteosarcoma
Currently open trials in the same condition.
- NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
- NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
- NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
- NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
- NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
Other Changye Zou trials
Trials by the same sponsor.
- NCT06331104 — Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06162962 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changye Zou
- Last refreshed: 8 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06162962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing